Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9205392 | 0.81 | — | — | |
| SCHEMBL5940456 | 0.75 | TSHR (0.38) | TSHRLMNATHRB | |
| SCHEMBL1260830 | 0.74 | — | — | |
| SCHEMBL537511 | 0.73 | LMNA (0.37) | TSHRLMNATHRB | |
| SCHEMBL3965325 | 0.72 | LMNA (0.30) | TSHRLMNA | |
| SCHEMBL23549404 | 0.71 | ADRB2 (0.35) | TSHRLMNATHRB | |
| SCHEMBL703661 | 0.71 | LMNA (0.35) | TSHRLMNATHRB | |
| SCHEMBL11598761 | 0.71 | TSHR (0.33) | TSHRLMNATHRB | |
| SCHEMBL17088158 | 0.71 | TSHR (0.33) | TSHRLMNATHRB | |
| SCHEMBL28593182 | 0.71 | TSHR (0.33) | TSHRLMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8519158-B2 | Androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2013-08-27 | — | — | US | claimed |
| US-20070254875-A1 | Androgen Receptor Modulator Compounds and Methods | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2007-11-01 | — | — | US | claimed |
| US-20050288525-A1 | Reagents for asymmetric allylation, aldol, and tandem aldol and allylation reactions | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-12-29 | — | — | US | claimed |
| WO-2005090282-A1 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2005-09-29 | — | — | WO | claimed |
| EP-1480988-A1 | REAGENTS FOR ASYMMETRIC ALLYLATION, ALDOL, AND TANDEM ALDOL AND ALLYLATION REACTIONS | The Trustees of Columbia University in the City of New York (US) | 2004-12-01 | — | — | EP | claimed |
| WO-2003074534-A9 | REAGENTS FOR ASYMMETRIC ALLYLATION, ALDOL, AND TANDEM ALDOL AND ALLYLATION REACTIONS | UNIV COLUMBIA (US) | 2003-11-20 | — | — | WO | claimed |
| WO-2003074534-A1 | REAGENTS FOR ASYMMETRIC ALLYLATION, ALDOL, AND TANDEM ALDOL AND ALLYLATION REACTIONS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2003-09-12 | — | — | WO | claimed |
| US-9359285-B2 | Androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2016-06-07 | — | — | US | disclosed |
| US-20150099720-A1 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2015-04-09 | — | — | US | disclosed |
| US-8865918-B2 | Androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2014-10-21 | — | — | US | disclosed |
| US-20140005186-A1 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2014-01-02 | — | — | US | disclosed |
| US-8519158-B2 | Androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2013-08-27 | — | — | US | disclosed |
| US-20090221816-A1 | Process for the Asymmetric Epoxidation of Olefins | LANXESS DEUTSCHLAND GMBH (DE) | 2009-09-03 | — | — | US | disclosed |
| US-20050288525-A1 | Reagents for asymmetric allylation, aldol, and tandem aldol and allylation reactions | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-12-29 | — | — | US | disclosed |
| WO-2005090282-A1 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2005-09-29 | — | — | WO | disclosed |
| US-20050203303-A1 | Process for the asymmetric epoxidation of olefins | LANXESS DEUTSCHLAND GMBH (DE) | 2005-09-15 | — | — | US | disclosed |
| EP-1561750-A1 | Process for asymmetric epoxidation of olefins | Lanxess Deutschland GmbH (DE) | 2005-08-10 | — | — | EP | disclosed |
| EP-1480988-A1 | REAGENTS FOR ASYMMETRIC ALLYLATION, ALDOL, AND TANDEM ALDOL AND ALLYLATION REACTIONS | The Trustees of Columbia University in the City of New York (US) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003074534-A9 | REAGENTS FOR ASYMMETRIC ALLYLATION, ALDOL, AND TANDEM ALDOL AND ALLYLATION REACTIONS | UNIV COLUMBIA (US) | 2003-11-20 | — | — | WO | disclosed |
| WO-2003074534-A1 | REAGENTS FOR ASYMMETRIC ALLYLATION, ALDOL, AND TANDEM ALDOL AND ALLYLATION REACTIONS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099720-A1 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | AR, SHBG, NR5A1 | TSHR 280/4885LMNA 3870/4885THRB 130/4885 |
| US-20050203303-A1 | Process for the asymmetric epoxidation of olefins | DUOX1, DUOX2, PPOX | TSHR 4682/4885LMNA 4838/4885THRB 4703/4885 |
| US-20140005186-A1 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | AR, SHBG, NR5A1 | TSHR 280/4885LMNA 3870/4885THRB 130/4885 |
| US-20090221816-A1 | Process for the Asymmetric Epoxidation of Olefins | DUOX1, DUOX2, PPOX | TSHR 4682/4885LMNA 4838/4885THRB 4703/4885 |
| US-20050288525-A1 | Reagents for asymmetric allylation, aldol, and tandem aldol and allylation reactions | AKR1C3, AKR1B10, CBR3 | TSHR 349/4885LMNA 1028/4885THRB 1735/4885 |
| US-20070254875-A1 | Androgen Receptor Modulator Compounds and Methods | AR, SHBG, NR5A1 | TSHR 280/4885LMNA 3870/4885THRB 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.